source
- England's NHS to fund AstraZeneca's Enhertu for metastatic breast cancer after U.K.-U.S. pricing pactEnglish health authorities have agreed to provide AstraZeneca's breast cancer drug Enhertu through the NHS, ending a multi-year dispute over its availability. The decision will make the drug acces…
- Novo and Orbis strike up to $1.4 billion partnership to develop oral peptide macrocycles for cardiometabolic diseaseNovo Pharmaceuticals has entered a partnership with fellow Danish firm Orbis Medicines that could be worth as much as $1.4 billion. The agreement includes upfront payments, downstream payouts and r…BioPharma Dive · 1mo agoDealPositive